Alexza Pharmaceuticals Appoints J. Kevin Buchi to its Board of Directors

   Alexza Pharmaceuticals Appoints J. Kevin Buchi to its Board of Directors

PR Newswire

MOUNTAIN VIEW, Calif., Jan. 3, 2013

MOUNTAIN VIEW, Calif., Jan. 3, 2013 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) announced today that J. Kevin Buchi has been appointed to
its Board of Directors. Mr. Buchi has more than 30 years of pharmaceutical
industry experience. Most recently, Mr. Buchi was Corporate Vice President,
Global Branded Products at Teva Pharmaceutical Industries. Mr.Buchi served at
Teva from October 2011 until May 2012.

"We are very pleased to welcome Kevin to our Board of Directors," said Thomas
B. King, President and CEO of Alexza Pharmaceuticals, Inc. "This will be a
transitional year for us, as we move from a development-stage company to a
commercial company with the launch of ADASUVE.Kevin brings a wealth of
experience and expertise to our Board, particularly in product
commercialization, partnering and overall corporate development.We look
forward to his contributions to Alexza's next phase."

Mr.Buchi served as Chief Executive Officer of Cephalon, Inc. from December
2010 through its acquisition by Teva in October 2011. Mr.Buchi joined
Cephalon in 1991 and held the positions of Chief Operating Officer and Chief
Financial Officer before becoming its Chief Executive Officer.From January
2010 through December 2010 as Chief Operating Officer, he managed the
company's global sales and marketing functions, as well as product
manufacturing, business development and investor relations. From 2006 through
2010, Mr.Buchi served as Chief Financial Officer. At various times in his
career at Cephalon, Mr.Buchi had oversight of corporate finance, accounting,
information systems, facilities, human resources and administration.

Mr.Buchi graduated from Cornell University with a B.A. in chemistry.He was a
synthetic organic chemist for the Eastman Kodak Company before going on to
obtain a Masters of Management from the J.L. Kellogg Graduate School of
Management at Northwestern University.

Mr. Buchi currently serves on the Board of Directors of Stemline Therapeutics
and Forward Pharma A/S.Previously, Mr. Buchi served on the Board of Directors
of Lorus Therapeutics (Canada), Encysive Pharmaceuticals, Celator
Pharmaceuticals and Mesoblast Limited (Australia).

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato^® system,
a hand-held inhaler that is designed to deliver a drug aerosol to the deep
lung, providing rapid systemic delivery and therapeutic onset with ease and
convenience for patients..

ADASUVE^® Staccato (loxapine) inhalation powder is Alexza's first product
approved by the U.S. Food and Drug Administration. Grupo Ferrer
Internacional, S.A. is Alexza's commercial partner for ADASUVE in Europe,
Latin America, Russia and the Commonwealth of Independent States countries.
Alexza has filed the ADASUVE Marketing Authorization Application with the
European Medicines Agency and recently received a positive opinion from the
Committee for Medicinal Products for Human Use. The European Commission,
which has the authority to grant marketing authorization for medicinal
products in the EU, is expected to deliver its decision on the ADASUVE
marketing authorization in the first quarter of 2013.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit more
information about ADASUVE, including the full prescribing information and
boxed warning, please visit^® and Staccato^® are
registered trademarks of Alexza Pharmaceuticals, Inc.

Safe Harbor Statement
This news release contains forward-looking statements that involve significant
risks and uncertainties. Any statement describing the Company's expectations
or beliefs is a forward-looking statement, as defined in the Private
Securities Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and uncertainties,
particularly those inherent in the process of developing and commercializing
drugs, including the ability for Alexza to effectively and profitably
commercialize ADASUVE in the US, the impact and risks of the ADASUVE
post-marketing studies and Risk Evaluation and Mitigation Strategy on the
commercialization of ADASUVE in the US, the timing and prospects for
regulatory approval to market ADASUVE in the EU, if approved for marketing in
the EU, the ability for Alexza and Ferrer to effectively and profitably
commercialize ADASUVE, the adequacy of the Company's capital to support the
Company's operations, and the Company's ability to raise additional funds and
the potential terms of such potential financings. The Company's
forward-looking statements also involve assumptions that, if they prove
incorrect, would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other risks
concerning Alexza's business are described in additional detail in the
Company's Annual Report on Form 10-K for the year ended December 31, 2011 and
the Company's other Periodic and Current Reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this announcement
are made as of this date, and the Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Contact: Thomas B. King, President and CEO, +1-650-944-7634,;
BCC Partners, Karen L. Bergman and Michelle Corral, +1-650-575-1509 or
+1-415-794-8662, or
Press spacebar to pause and continue. Press esc to stop.